We are live on
!
Find out more
BCM
Boone Capital Management Portfolio holdings
AUM
$428M
1-Year Est. Return
136.02%
This Fund
S&P 500
This Quarter
Est. Return
+22.36%
1 Year Est. Return
+136.02%
3 Year Est. Return
+278.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$428M
AUM Growth
+$101M
(+31%)
Cap. Flow
+$49.3M
Cap. Flow
% of AUM
11.53%
Top 10 Holdings %
Top 10 Hldgs %
83.01%
Holding
20
New
7
Increased
8
Reduced
1
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vestis
VSTS
|
+$21.2M |
| 2 |
Pennant Group
PNTG
|
+$16.8M |
| 3 |
Teleflex
TFX
|
+$13.9M |
| 4 |
Monte Rosa Therapeutics
GLUE
|
+$11.6M |
| 5 |
Tango Therapeutics
TNGX
|
+$11.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$34.5M |
| 2 |
AstraZeneca
AZN
|
+$21.7M |
| 3 |
AVNS
Avanos Medical
AVNS
|
+$16.6M |
| 4 |
Tenax Therapeutics
TENX
|
+$3.2M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
+$562K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.55% |
| 2 | Industrials | 6.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Teleflex
TFX
$5.55B
| $49.1M | 11.49% |
387,388
+108,596
| +39% | +$13.9M |
|
|
2
Mirum Pharmaceuticals
MIRM
$6.28B
| $48.7M | 11.38% |
415,641
-5,595
| -1% | -$562K |
|
3
Cigna
CI
$74.2B
| $43.9M | 10.27% |
159,290
+21,768
| +16% | +$6.15M |
|
4
Ionis Pharmaceuticals
IONS
$8.55B
| $41.2M | 9.64% |
519,977
+19,455
| +4% | +$1.46M |
|
5
UnitedHealth
UNH
$344B
| $36.9M | 8.62% |
88,687
+9,461
| +12% | +$3.51M |
|
6
BioMarin Pharmaceuticals
BMRN
$12.7B
| $33.4M | 7.81% |
583,219
+35,348
| +6% | +$1.94M |
|
|
GRDN
7
Guardian Pharmacy Services
GRDN
$2.94B
| $29.8M | 6.97% |
711,939
+80,746
| +13% | +$3.13M |
|
|
8
Vestis
VSTS
$1.71B
| $27.6M | 6.45% |
+1,900,140
| New | +$21.2M |
|
9
BridgeBio Pharma
BBIO
$14.1B
| $25.3M | 5.92% |
339,720
+110,891
| +48% | +$7.77M |
|
|
10
Pennant Group
PNTG
$1.4B
| $19.1M | 4.46% |
+515,818
| New | +$16.8M |
|
|
11
Monte Rosa Therapeutics
GLUE
$1.2B
| $14.9M | 3.48% |
+615,287
| New | +$11.6M |
|
12
Kodiak Sciences
KOD
$2.08B
| $14.7M | 3.44% |
378,010
+96,678
| +34% | +$3.76M |
|
|
13
Tango Therapeutics
TNGX
$4.01B
| $14.2M | 3.33% |
+455,605
| New | +$11.3M |
|
14
Kymera Therapeutics
KYMR
$9.53B
| $13M | 3.04% |
+113,173
| New | +$9.72M |
|
15
Cullinan Oncology
CGEM
$1.33B
| $12.8M | 3% |
+704,442
| New | +$10.5M |
|
|
ANL
16
Adlai Nortye Group ADS
ANL
$979M
| $2.97M | 0.7% |
+258,390
| New | +$3.14M |
|
|
AVNS
17
DELISTED
Avanos Medical
AVNS
| – | – |
-1,184,909
| Closed | -$16.6M |
|
|
18
AstraZeneca
AZN
$254B
| – | – |
-110,101
| Closed | -$21.7M |
|
|
19
Medtronic
MDT
$120B
| – | – |
-398,065
| Closed | -$34.5M |
|
|
20
Tenax Therapeutics
TENX
$69.6M
| – | – |
-200,000
| Closed | -$3.2M |
|
Similar funds
BTD
SCS
DL
SPWM
DMC
S
IAA
T
Boone Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Boone Capital Management held 20 positions worth $428M, up 31% from $326M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Boone Capital Management deployed $49.3M of net new capital in Q2 2026, opening 7 new positions and adding to 8 existing holdings. Its largest new stake was Vestis: 1,900,140 shares worth $27.6M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 100% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was Mirum Pharmaceuticals, an estimated $562K trimmed.
- Boone Capital Management's largest Q2 2026 buy was Vestis: 1,900,140 shares worth $27.6M.
- Boone Capital Management added most to Teleflex in Q2 2026, an estimated $13.9M increase.
- Boone Capital Management's biggest Q2 2026 reduction was Mirum Pharmaceuticals, cutting an estimated $562K.
- Boone Capital Management fully exited Medtronic in Q2 2026, selling an estimated $34.5M.
- Boone Capital Management's ten largest holdings make up 83% of its $428M portfolio in Q2 2026.
- Boone Capital Management opened 7 new positions and closed 4 in Q2 2026.
- Boone Capital Management's portfolio value rose 31% quarter-over-quarter to $428M.
Based on Boone Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.